OneSource Specialty Pharma Ltd

- OneSource Specialty Pharma plans no regular debt on the base business, expecting to be debt-free by FY28 steady state. - Guidance includes potential debt up to 1.5x EBITDA peak for FY28 due to ongoing investments, especially in biologics and microbial capacity expansions. - Capex plans (~INR700+ crores) are largely committed and fully funded through strong relationships with global and Indian bankers. - The company expects short-term capex-related debt increase but remains confident in fundamentals and shareholder value creation. - No mention of equity fundraising or issuance in the provided information. - Focus is on managing cash flows, reducing interest rates (now 200 bps lower at under 9%), and leveraging digital controls for financial discipline.

- OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site expansion, particularly in the DDC (Drug Device Combination) business. - By end of FY27, installed new capacities worth around $200 million are expected, with incremental capacity enhancements happening throughout the year. - Investments include building microbial capacity for biologics CDMO, considered unique and competitive. - Capex plans also cover expansion in lyophilization and new capabilities at the general injectables site in Bangalore. - Around three-quarters of the planned $100 million capex for the flagship site have already been committed. - The company works closely with partners and regulators to get approvals for scaling batch sizes to improve efficiency and cost competitiveness. - Despite near-term revenue recognition delays, capex funding is fully arranged via strong banking relationships with international lenders.

- Revenue affected short-term due to regulatory delays, especially in Canada, but strong recovery expected from FY '27 onwards. - FY '28 guidance reiterated with confidence to become a ₹400 crore revenue company organically. - Customer orders strengthening with an expanding product pipeline, including drug-device combinations and biologics. - Capacity expansion capex of over ₹700 crore progressing well; significant additional capacities expected by H2 FY '27. - Customer forecasts are being revised upward consistently, indicating growing demand. - Sequential quarter-on-quarter improvement anticipated starting FY '27 as approvals materialize. - Biologics CDMO business showing strong growth with RFPs almost 4x of previous levels and new major biosimilar customers onboarded. - Expansion into oncology assets with partnerships among top 10 U.S. generic companies. - Continued focus on increasing batch sizes to improve efficiency and competitiveness to support volume growth.

- FY '26 is a transitory year with focus on building operating capacity and scale readiness. - Q3 FY '26 revenue impacted by deferrals and regulatory delays; recovery expected as approvals come. - FY '27 expected to mark the beginning of material Commercial Supply Agreement (CSA) revenues, with H2 stronger than H1. - FY '28 guidance reiterated: target to become a INR 400 crore revenue company organically. - EBITDA and profitability expected to improve sequentially starting FY '27 as commercial supplies ramp up. - Long-term margin sustainability supported by strong cash flows, digital cost controls, and process strengthening. - Working capital normalized over FY '27 with inventory build-up being temporary and customer-backed. - Debt-to-EBITDA expected below 1.5x by FY '28; steady-state business expected to be debt-free by then. - EPS turnaround anticipated with increasing revenues and operational leverage post FY '27.

- OneSource has strong visibility from customers, including long-term commitments extending beyond three years. - They prioritize commercial sales over MSAs (Manufacturing Service Agreements) to optimize capacity utilization and economics. - Customer orders continue to strengthen despite near-term approval delays. - Customer forecasts are being revised upwards consistently, reflecting confidence in future demand. - The company has been renegotiating take-or-pay contracts to secure more structured, longer-term relationships. - Inventory build-up for significant upcoming semaglutide launches is customer-backed with advances or firm purchase orders. - The new oncology contract with a large company indicates growth opportunities, with supplies expected to start as approvals come through. - Despite two soft quarters' impact on revenue, sequential improvement is expected as market approvals materialize between February and May 2026.